title: Novel pharmacotherapy of sarcoidosis.
abstract: Sarcoidosis is a multisystem granulomatous disease of unknown etiology that most commonly affects the lungs. Treatment of sarcoidosis can be challenging as it is often difficult to measure disease activity and distinguish active inflammation from fibrosis. Identifying the inflammatory mediators in sarcoidosis has led to the development and use of novel therapeutic agents. The goal of pharmacotherapy is to decrease granuloma accumulation, ameliorate symptoms and improve organ function. Systemic corticosteroids remain the first line treatment. Other immunosuppressive agents may be considered for the patients who respond poorly to corticosteroids or who experience significant adverse effects. An overview of pharmacotherapy of sarcoidosis is provided here.
authors.affiliation: SUNY Upstate Medical University, Syracuse, NY, USA. Electronic address: sahb@upstate.edu.
authors.forename: Birendra P
authors.initials: BP
authors.lastname: Sah
authors.affiliation: SUNY Upstate Medical University, Syracuse, NY, USA.
authors.forename: Shraddha
authors.initials: S
authors.lastname: Goyal
authors.affiliation: SUNY Upstate Medical University, Syracuse, NY, USA.
authors.forename: Michael C
authors.initials: MC
authors.lastname: Iannuzzi
mesh_terms: D000305:Adrenal Cortex Hormones / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use; D012507:Sarcoidosis / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000305:Adrenal Cortex Hormones; D007155:Immunologic Factors
keywords: Corticosteroids; Immunosuppressive agents; Pulmonary; Sarcoidosis; Symptoms; Treatment